» Articles » PMID: 27696525

Melatonin Alleviates Postinfarction Cardiac Remodeling and Dysfunction by Inhibiting Mst1

Overview
Journal J Pineal Res
Publisher Wiley
Specialty Endocrinology
Date 2016 Oct 4
PMID 27696525
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Melatonin reportedly protects against several cardiovascular diseases including ischemia/reperfusion (I/R), atherosclerosis, and hypertension. The present study investigated the effects and mechanisms of melatonin on cardiomyocyte autophagy, apoptosis, and mitochondrial injury in the context of myocardial infarction (MI). We demonstrated that melatonin significantly alleviated cardiac dysfunction after MI. Four weeks after MI, echocardiography and Masson staining indicated that melatonin notably mitigated adverse left ventricle remodeling. The mechanism may be associated with increased autophagy, reduced apoptosis, and alleviated mitochondrial dysfunction. Furthermore, melatonin significantly inhibited Mst1 phosphorylation while promoting Sirt1 expression after MI, which indicates that Mst1/Sirt1 signaling may serve as the downstream target of melatonin. We thus constructed a MI model using Mst1 transgenic (Mst1 Tg) and Mst1 knockout (Mst1 ) mice. The absence of Mst1 abolished the favorable effects of melatonin on cardiac injury after MI. Consistently, melatonin administration did not further increase autophagy, decrease apoptosis, or alleviate mitochondrial integrity and biogenesis in Mst1 knockout mice subjected to MI injury. These results suggest that melatonin alleviates postinfarction cardiac remodeling and dysfunction by upregulating autophagy, decreasing apoptosis, and modulating mitochondrial integrity and biogenesis. The attributed mechanism involved, at least in part, Mst1/Sirt1 signaling.

Citing Articles

Modulation of autophagy by melatonin and its receptors: implications in brain disorders.

Zhu C, Li G, Lyu H, Lu Y, Li Y, Zhang X Acta Pharmacol Sin. 2024; 46(3):525-538.

PMID: 39448859 PMC: 11845611. DOI: 10.1038/s41401-024-01398-2.


Exploring Sirtuins: New Frontiers in Managing Heart Failure with Preserved Ejection Fraction.

Lu Y, Li Y, Xie Y, Bu J, Yuan R, Zhang X Int J Mol Sci. 2024; 25(14).

PMID: 39062982 PMC: 11277469. DOI: 10.3390/ijms25147740.


SIRT3 and RORα are two prospective targets against mitophagy during simulated ischemia/reperfusion injury in H9c2 cells.

Wu J, Yang Y, Lin D, Wang Z, Ma J Heliyon. 2024; 10(10):e30568.

PMID: 38784556 PMC: 11112282. DOI: 10.1016/j.heliyon.2024.e30568.


The Current State of Research on Sirtuin-Mediated Autophagy in Cardiovascular Diseases.

Wang Y, Li Y, Ding H, Li D, Shen W, Zhang X J Cardiovasc Dev Dis. 2023; 10(9).

PMID: 37754811 PMC: 10531599. DOI: 10.3390/jcdd10090382.


The hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy.

Yin Y, Tan M, Han L, Zhang L, Zhang Y, Zhang J Acta Pharm Sin B. 2023; 13(5):1956-1975.

PMID: 37250161 PMC: 10213817. DOI: 10.1016/j.apsb.2023.01.015.